close

InterMune, Inc., a biotechnology company, focuses on the research, development, and commercialization of therapies in pulmonology and hepatology. It offers Actimmune for the treatment of patients with severe, malignant osteopetrosis, and chronic granulomatous disease in the United States. The company has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes CAPACITY, a Phase III program evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF; and a research program focusing on pirfenidone analog ITMN-520. The hepatology portfolio comprises the HCV protease inhibitor compound ITMN-191, which is in Phase Ib, a second-generation HCV protease inhibitor research program; and a research program evaluating a new target in hepatology. It has license and collaboration agreements with Maxygen Holdings Ltd.; Array BioPharma, Inc.; Boehringer Ingelheim International GmbH; Hoffmann-LaRoche Inc. and F. Hoffmann-LaRoche Ltd.; Novartis Corporation; Connetics Corporation; Eli Lilly & Company; Genentech, Inc.; ALZA Corporation; Amgen Inc; and Marnac, Inc. and its co-licensor, /KDL GmbH. The company was founded in 1998 and is headquartered in Brisbane, California.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	14.80
Volume	(mio) 1.31
Volume Avg	(mio) 2.45
52 Week High	51.71
52 Week Low	10.67
PE	N/A
PE (group average)	39
EPS Year	-2.58
EPS change Q/Q	1000%
EPS change Q/Q Yr ago	-13.64%
EPS change Q/Q next Q est	-19.72%
EPS change Y/Y	1000%
REV change Q/Q	-97.35%
REV change Q/Q Yr ago	4.92%
EPS next Q est	-0.71
EPS next Y est	-1.29
Divident Annual	0.00
Dividend Yield	0%